(Total Views: 150)
Posted On: 01/12/2022 2:33:20 PM
Post# of 38430
Huge $QNTA News yesterday, way oversold.
Medolife’s product, Escozine, which is registered as an alternative oncological medicine in the DR, and anticipates seeking approval as a COVID 19 treatment in both the United States, under PIND #150335, and the DR. The peptides obtained from the scorpion venom are used by the Company in combination with their patented polarization technology to create an ever-growing line of drugs and nutraceuticals.
News January 11, 2022
Medolife Rx Presents Its Venom-To-Drug Development Projects at an International Conference Held in the Dominican Republic https://finance.yahoo.com/news/medolife-rx-pr...00894.html
Medolife’s product, Escozine, which is registered as an alternative oncological medicine in the DR, and anticipates seeking approval as a COVID 19 treatment in both the United States, under PIND #150335, and the DR. The peptides obtained from the scorpion venom are used by the Company in combination with their patented polarization technology to create an ever-growing line of drugs and nutraceuticals.
News January 11, 2022
Medolife Rx Presents Its Venom-To-Drug Development Projects at an International Conference Held in the Dominican Republic https://finance.yahoo.com/news/medolife-rx-pr...00894.html
(0)
(0)
